High Expression of Ubiquitin-Specific Protease 39 and Its Roles in Prognosis in Patients with Hepatocellular Carcinoma

Table 1

Clinical features with differentially expressed USP39 in HCC.

Characteristic	n	Low expression of USP39	High expression of USP39
T stage, n (%)				0.006
T1	183	107 (58.2%)	76 (40.6%)
T2	95	42 (22.8%)	53 (28.4%)
T3	80	31 (16.8%)	49 (26.2%)
T4	13	4 (2.2%)	9 (4.8%)
N stage, n (%)				0.624
N0	254	122 (99.2%)	132 (97.8%)
N1	4	1 (0.8%)	3 (2.2%)
M stage, n (%)				0.623
M0	268	132 (99.2%)	136 (97.8%)
M1	4	1 (0.8%)	3 (2.2%)
Pathologic stage, n (%)				0.009
Stage I	173	100 (57.5%)	73 (41.5%)
Stage II	87	41 (23.6%)	46 (26.1%)
Stage III	85	31 (17.8%)	54 (30.7%)
Stage IV	5	2 (1.1%)	3 (1.7%)
Tumor status, n (%)				0.006
Tumor free	202	114 (64.4%)	88 (49.4%)
With tumor	153	63 (35.6%)	90 (50.6%)
Gender, n (%)				0.185
Female	121	54 (28.9%)	67 (35.8%)
Male	253	133 (71.1%)	120 (64.2%)
Age, n (%)				0.043
≤ 60	177	78 (41.9%)	99 (52.9%)
>60	196	108 (58.1%)	88 (47.1%)
Median (IQR)	123	64 (54, 70)	59 (51, 67)	0.005
Residual tumor, n (%)				0.083
R0	327	170 (96.6%)	157 (92.9%)
R1	17	5 (2.8%)	12 (7.1%)
R2	1	1 (0.6%)	0 (0.0%)
Histologic grade, n (%)				0.002
G1	55	35 (18.9%)	20 (10.9%)
G2	178	98 (53.0%)	80 (43.5%)
G3	124	49 (26.5%)	75 (40.7%)
G4	12	3 (1.6%)	9 (4.9%)
Vascular invasion, n (%)				0.072
No	208	118 (70.2%)	90 (60.0%)
Yes	110	50 (29.8%)	60 (40.0%)

IQR: interquartile range.